New drug ORB-021 enters human testing for Hard-to-Treat cancers
NCT ID NCT06607939
First seen Feb 10, 2026 · Last updated May 01, 2026 · Updated 10 times
Summary
This early-phase study tests whether the investigational drug ORB-021 is safe and tolerable in 36 adults with advanced solid tumors that have not responded to standard treatments. Researchers will also find the best dose for future studies. Participants will go through screening, treatment, and follow-up phases.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Honor Health Clinical Research
RECRUITINGScottsdale, Arizona, 85258, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
MDAC
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.